

UMR Medical Policy Update Bulletin *Quick View:* September 2025



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: September 2025](#).**

Take Note

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates

Beginning **Oct. 1, 2025**, all applicable Medical Policies and Medical Benefit Drug Policies will be updated to reflect the annual ICD-10 and quarterly CPT/HCPCS code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- [American Medical Association: Current Procedural Terminology: CPT®](#)
- [Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System \(HCPCS\) Quarterly Update](#)
- [Centers for Medicare & Medicaid Services: International Classification of Diseases, Tenth Revision \(ICD-10\) Codes](#)

Complete details on impacted policies and corresponding code edits will be provided in the October 2025 edition of the Medical Policy Update Bulletin.

Medical Policy Updates

Policy Title	Status	Effective Date
Autologous Cellular Therapy	Updated	Oct. 1, 2025
Cognitive Rehabilitation and Coma Stimulation	Revised	Oct. 1, 2025
Diagnostic Spinal Ultrasonography	Retired	Sep. 1, 2025
Electric Tumor Treatment Field Therapy	Revised	Oct. 1, 2025
Genetic Testing for Cardiac Disease	Revised	Oct. 1, 2025
Glaucoma Surgical Treatments	Revised	Oct. 1, 2025
Hospital Services: Observation and Inpatient	Revised	Oct. 1, 2025
Neuropsychological Testing Under the Medical Benefit	Retired	Sep. 1, 2025
Skin and Soft Tissue Substitutes	Revised	Oct. 1, 2025
Surgery of the Ankle	Revised	Oct. 1, 2025
Sympathetic Blockade	Updated	Sep. 1, 2025
Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver	Revised	Oct. 1, 2025
Transcatheter Procedures for Heart Valve Conditions	Revised	Oct. 1, 2025

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Clotting Factors, Coagulant Blood Products, & Other Hemostatics	Revised	Oct. 1, 2025
Gamifant® (Emapalumab-Lzsg)	Revised	Oct. 1, 2025
Maximum Dosage and Frequency	Revised	Oct. 1, 2025

Policy Title	Status	Effective Date
Oncology Medication Clinical Coverage	Revised	Oct. 1, 2025
White Blood Cell Colony Stimulating Factors	Revised	Oct. 1, 2025
Xolair® (Omalizumab)	Revised	Oct. 1, 2025

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

UMR is a wholly owned subsidiary of UnitedHealthcare, a part of UnitedHealth Group. UMR is a third-party administrator (TPA) for self-funded plans.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UMR Medical Policies and Medical Benefit Drug Policies is available at UHCprovider.com/policies > For Commercial Plans > [UnitedHealthcare](#) | [UMR Medical & Drug Policies](#).